Beyond Highs: The Complex Signaling of Your Body's Cannabinoid System
In short: Cannabinoids aren't just for recreation; they are part of a sophisticated biological signaling network. From regulating appetite and immunity to influencing physical exercise, these receptors mediate vital functions across the body. Understanding their nuanced pharmacology is the key to unlocking next-generation therapies for chronic pain and neurological disorders.
The endocannabinoid system (ECS) utilizes two primary G protein-coupled receptors: CB1 and CB2. While CB1 is predominantly expressed in the central nervous system—including areas like the brain, lungs, liver, and kidneys—CB2 is primarily found in the immune system and hematopoietic cells. These receptors are activated by various ligands, including plant-derived phytocannabinoids like THC, as well as endogenous cannabinoids produced naturally by the body. The protein sequences of these two receptor subtypes share approximately 44% similarity overall. However, when focusing strictly on the transmembrane regions, that amino acid similarity increases to about 68%. Both receptors are characterized by seven transmembrane spanning domains.
Research highlights a sophisticated mechanism of 'retrograde signaling.' In this process, endocannabinoids are released from a post-synaptic neuron and bind to CB1 receptors on the pre-synaptic neuron. This interaction can lead to depolarization-induced suppression of inhibition, effectively reducing the release of neurotransmitters like GABA. Beyond the brain, the ECS plays significant roles in metabolic regulation—influencing obesity and hyperglycemia—and even interacts with physical exercise pathways. The neurotransmitter anandamide was first identified in 1992 and is derived from the Sanskrit word for bliss. Other fatty acid transmitters also behave as endogenous cannabinoids with varying levels of efficacy. These molecules are lipophilic in nature.
Current pharmacological research is shifting toward 'allosteric modulators.' Unlike classical drugs that bind to the main active site, positive and negative allosteric modulators (PAMs and NAMs) target secondary sites on the CB1 receptor. This approach offers a more precise way to tune receptor activity. However, challenges remain; for instance, high-potency synthetic cannabinoid receptor agonists (SCRAs) have shown significant neurotoxicity in studies involving rat cortical neurons, causing mitochondrial dysfunction and cell death at nanomolar concentrations. Recent studies have focused on identifying multiple allosteric sites specifically on the CB1 receptor to facilitate structure-based drug discovery. This research aims to move beyond simple agonists to create more nuanced therapeutic agents for conditions like epilepsy and chemotherapy-induced nausea.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery - Acta Pharmacologica Sinica
- Also: Cannabinoid receptor
- Also: Neurotoxicity of Synthetic Cannabinoid Receptor Agonist Cumyl-PINACA: An In Vitro Study on Rat Cortical Neurons and Astrocytes.
To cite this card, link to https://intellectplus.co.uk/app/health-cannabinoid-receptor.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Exercise & fitness · More in Health · Latest · A–Z · All topics
